vs
Apellis Pharmaceuticals, Inc.（APLS）与维珍大西洋航空（ATLN）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是维珍大西洋航空的1.7倍（$199.9M vs $120.0M），维珍大西洋航空净利率更高（-22.6% vs -29.5%，领先6.9%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -7.3%），维珍大西洋航空自由现金流更多（$-8.2M vs $-14.3M），过去两年维珍大西洋航空的营收复合增速更高（9.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
维珍大西洋航空（简称维珍航空）是英国知名航空公司，总部位于英格兰西萨塞克斯郡克劳利。该公司成立于1984年，最初名为不列颠大西洋航空，创始人原本计划开通伦敦至福克兰群岛的航线，更名后创始人之一将股份售予理查德·布兰森，如今是英国航空市场的核心运营商之一。
APLS vs ATLN — 直观对比
营收规模更大
APLS
是对方的1.7倍
$120.0M
营收增速更快
APLS
高出1.4%
-7.3%
净利率更高
ATLN
高出6.9%
-29.5%
自由现金流更多
ATLN
多$6.1M
$-14.3M
两年增速更快
ATLN
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $120.0M |
| 净利润 | $-59.0M | $-27.1M |
| 毛利率 | — | 9.1% |
| 营业利润率 | -25.6% | -19.5% |
| 净利率 | -29.5% | -22.6% |
| 营收同比 | -5.9% | -7.3% |
| 净利润同比 | -62.2% | 60.5% |
| 每股收益（稀释后） | $-0.40 | $-0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSATLN
| Q4 25 | $199.9M | $120.0M | ||
| Q3 25 | $458.6M | $110.1M | ||
| Q2 25 | $178.5M | $102.9M | ||
| Q1 25 | $166.8M | $102.8M | ||
| Q4 24 | $212.5M | $129.5M | ||
| Q3 24 | $196.8M | $107.8M | ||
| Q2 24 | $199.7M | $104.6M | ||
| Q1 24 | $172.3M | $100.6M |
净利润APLSATLN
| Q4 25 | $-59.0M | $-27.1M | ||
| Q3 25 | $215.7M | $-10.8M | ||
| Q2 25 | $-42.2M | $-10.7M | ||
| Q1 25 | $-92.2M | $-10.7M | ||
| Q4 24 | $-36.4M | $-68.7M | ||
| Q3 24 | $-57.4M | $-7.0M | ||
| Q2 24 | $-37.7M | $-54.9M | ||
| Q1 24 | $-66.4M | $-4.9M |
毛利率APLSATLN
| Q4 25 | — | 9.1% | ||
| Q3 25 | — | 11.3% | ||
| Q2 25 | — | 11.1% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | — | 11.0% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 10.4% |
营业利润率APLSATLN
| Q4 25 | -25.6% | -19.5% | ||
| Q3 25 | 48.7% | -7.9% | ||
| Q2 25 | -18.6% | -8.4% | ||
| Q1 25 | -50.0% | -9.2% | ||
| Q4 24 | -12.3% | -4.5% | ||
| Q3 24 | -24.0% | -6.0% | ||
| Q2 24 | -14.7% | -7.9% | ||
| Q1 24 | -36.0% | -1.1% |
净利率APLSATLN
| Q4 25 | -29.5% | -22.6% | ||
| Q3 25 | 47.0% | -9.8% | ||
| Q2 25 | -23.6% | -10.4% | ||
| Q1 25 | -55.3% | -10.5% | ||
| Q4 24 | -17.1% | -53.0% | ||
| Q3 24 | -29.2% | -6.5% | ||
| Q2 24 | -18.9% | -52.5% | ||
| Q1 24 | -38.5% | -4.8% |
每股收益（稀释后）APLSATLN
| Q4 25 | $-0.40 | $-0.48 | ||
| Q3 25 | $1.67 | $-0.20 | ||
| Q2 25 | $-0.33 | $-0.20 | ||
| Q1 25 | $-0.74 | $-0.20 | ||
| Q4 24 | $-0.30 | $-1.37 | ||
| Q3 24 | $-0.46 | $-0.16 | ||
| Q2 24 | $-0.30 | $-1.96 | ||
| Q1 24 | $-0.54 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $81.1K |
| 总债务越低越好 | — | $84.7M |
| 股东权益账面价值 | $370.1M | $-32.1M |
| 总资产 | $1.1B | $113.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSATLN
| Q4 25 | $466.2M | $81.1K | ||
| Q3 25 | $479.2M | $83.4K | ||
| Q2 25 | $370.0M | $374.7K | ||
| Q1 25 | $358.4M | $1.5M | ||
| Q4 24 | $411.3M | $678.7K | ||
| Q3 24 | $396.9M | $1.4M | ||
| Q2 24 | $360.1M | $439.5K | ||
| Q1 24 | $325.9M | $1.7M |
总债务APLSATLN
| Q4 25 | — | $84.7M | ||
| Q3 25 | — | $76.4M | ||
| Q2 25 | — | $75.4M | ||
| Q1 25 | — | $66.9M | ||
| Q4 24 | — | $80.6M | ||
| Q3 24 | — | $80.8M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | $93.1M | — |
股东权益APLSATLN
| Q4 25 | $370.1M | $-32.1M | ||
| Q3 25 | $401.2M | $-22.1M | ||
| Q2 25 | $156.3M | $-18.5M | ||
| Q1 25 | $164.2M | $-14.0M | ||
| Q4 24 | $228.5M | $-12.0M | ||
| Q3 24 | $237.1M | $16.2M | ||
| Q2 24 | $264.3M | $23.0M | ||
| Q1 24 | $266.7M | $16.8M |
总资产APLSATLN
| Q4 25 | $1.1B | $113.2M | ||
| Q3 25 | $1.1B | $110.3M | ||
| Q2 25 | $821.4M | $106.8M | ||
| Q1 25 | $807.3M | $106.5M | ||
| Q4 24 | $885.1M | $119.8M | ||
| Q3 24 | $901.9M | $135.6M | ||
| Q2 24 | $904.5M | $134.2M | ||
| Q1 24 | $831.9M | $3.4M |
负债/权益比APLSATLN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.98× | ||
| Q2 24 | — | 3.41× | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-8.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-8.2M |
| 自由现金流率自由现金流/营收 | -7.1% | -6.8% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-4.5M |
8季度趋势，按日历期对齐
经营现金流APLSATLN
| Q4 25 | $-14.2M | $-8.2M | ||
| Q3 25 | $108.5M | $-1.3M | ||
| Q2 25 | $4.4M | $-9.5M | ||
| Q1 25 | $-53.4M | $14.6M | ||
| Q4 24 | $19.4M | $-426.3K | ||
| Q3 24 | $34.1M | $-1.3M | ||
| Q2 24 | $-8.3M | $-15.5M | ||
| Q1 24 | $-133.0M | $11.2M |
自由现金流APLSATLN
| Q4 25 | $-14.3M | $-8.2M | ||
| Q3 25 | $108.3M | $-1.3M | ||
| Q2 25 | $4.4M | $-9.5M | ||
| Q1 25 | $-53.4M | $14.6M | ||
| Q4 24 | $19.3M | $-449.4K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-8.4M | $-15.5M | ||
| Q1 24 | $-133.3M | $11.2M |
自由现金流率APLSATLN
| Q4 25 | -7.1% | -6.8% | ||
| Q3 25 | 23.6% | -1.2% | ||
| Q2 25 | 2.5% | -9.3% | ||
| Q1 25 | -32.0% | 14.2% | ||
| Q4 24 | 9.1% | -0.3% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | -4.2% | -14.8% | ||
| Q1 24 | -77.3% | 11.2% |
资本支出强度APLSATLN
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率APLSATLN
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ATLN
暂无分部数据
